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Summary: Bone alkaline phosphatase is a marker of osteoblast activity. In order to study the posttranscriptional
modification (glycosylation) of bone alkaline phosphatase in bone disease, we investigated the relationship between
mass and catalytic activity of bone alkaline phosphatase in patients with osteoporosis and hyperthyroidism. Serum
bone alkaline phosphatase aetivity was measured after lectin precipitation using the Iso-ALP test kit. Mass concen-
tration of bone alkaline phosphatase was determined with an immunoradiometric assay (Tandem-R Ostase). In
general, serum bone alkaline phosphatase mass and activity concentration correlated well. The activity : mass ratio
of bone alkaline phosphatase was low in hyperthyroidism. Activation energy of the reaction catalysed by bone
alkaline phosphatase was high in osteoporosis and in hyperthyroidism. Experiments with neuraminidase digestion
further demonstrated that the thermodynamic heterogeneity of bone alkaline phosphatase can be explained by a
different glycosylation of the enzyme.
Introduction tase) are products of a single gene and diflfer only äs a
TU 4. u v *· ·„ f ^ u *· u result of posttranslational modification (4, 5). PlacentalThe metabolic activity of human bone tissue can be r
studied in serum and urine. In serum, the circulating aUcaline PhosPhatase is characterized by multiple alleles
levels of alkaline phosphatase1) and its bone isoform, <6)· ™e differences between bone and liver alkaline
osteocalcin (bone Gla protein, BGP) and type I procolla- Phosphatase isoforms are due to the manner of sialic
gen are markers of osteoblast activity (bone formation) acid linkaSe aTld the attachment of the O-linked sugar
(l, 2). Total serum alkaline phosphatase activity is a less moiety (7).
specific marker because i t also partly-originales from , , , , . , ,
tissuesotherthanbone. Metbod$ used to separate bone alkahne PhosPhatase
from tlie other isoforms include electrophoresis, chemi-
The alkaline phosphatase activity in human serum may caj Inhibition and heat denaturation, but all these pro-
originate from the liver, the skeleton, the gastrointestinal cedures are technically difficult and have poor resolution
traet, the kidney, the placenta and certain tumours (3). (g) ̂  different properties of bone alkaline phospha-
Intestinal and placental alkaline phosphatase are true tase ^ Uver alkaüne phosphatase in these methods re_
isoenzymes encoded by separate genetic loci, while flect differences in glycosylation (9> 10), as confirmed
liver bone, renal and biliary alkaUne phosphatase (mac- ^ ̂ ^^ e iments with neuraminidase
romolecular hver fraction, liver fast alkaline phospha- / t - f ,, 0 „ „ „^ j -F (11). Rosalki & Tmg Foo (12) reported the selective
binding of wheat genn lectin (from Triticum vulgäre)
AlSTph'osphatase (Orthophosphoric-monoester phosphohydro- to bone alkaline P^sphatase and not to üver alkaline
läse (alkaline optimum); EC 3.1,3.1) phosphatase, which suggests that only bone alkaline
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phosphatase contains N-acetylglucosamine residues in
its carbohydrate moiety (13).
Two alternative techniques for quantitating bone alka-
line phosphatase based on lectin precipitation and mo-
noclonal antibodies are now available. We used both
methods to investigate the relationship between mass
and catalytic activity of bone alkaline phosphatase, in
order to study the modification of bone alkaline phos-
phatase. Furthermore, the catalytic quality of bone alka-
line phosphatase was evaluated by activation energy de-
termination. Two specific groups of patients with meta-




Blood was collected, allowed to clot and centrifuged (1000g, 10
min, 20 °C). The supernatant serum was collected for analysis. A
group of 14 healthy blood donors (age: 43 ± 14 years; 5 males, 9
females) was used s a contra l group. Thirty four patients with
osteoporosis (age: 57 ± 12 years; 8 males, 26 females) were
studied. The female osteoporosis group consisted of premenopausal
(n = 5) and post-menopausal (n = 21) women. Eight patients
(24%) had a bone fracture due to osteoporosis. All osteoporosis
patients underwent an axial bone densitometry. Concomitantly, pa-
tients with hyperthyroidism (n = 78; age: 52 ± 13 years; 28 males,
50 females) were studied. The subjects with clinical suspicion or
evidence of liver, biliary or renal disease and patients receiving
glucocorticoid therapy were excluded frorn analysis. None of the
female subjects examined was pregnant. Postmenopausal osteopo-
rotic women were not receiving any hormonal replacement therapy
at the time of study.
Measurement of total alkaline phosphatase activity
We determined alkaline phosphatase activity in serum at 37.0 °C
according to the IFCC recommendation (14) (Boehringer, Mann-
heim, Germany) on a HITACHI 747 analyser (Boehringer, Mann-
heim, Germany).
(IRMA) (17). The kit (Tandem-R Ostase, purchased from Hybri-
tech Inc., San Diego, CA, USA) utilizes two monoclonal antibodies
which are 7 times more reactive with bone alkaline phosphatase
than with liver alkaline phosphatase. The assay was run overnight
(incubation time: 19 h) at 2—8 °C. Measurements were made with
an LKB Wallace 1261 gamma-counter (Turku, Finland).
Determination of bone alkaline phosphatase activation
energy
We eluted bone alkaline phosphatase frorn the lectin precipitates
by adding 100 μΐ of N-aeetylglucosamine (Sigma Chemicals Co.,
St Louis, MO, USA), 45 mmol/1 in saline solution (12). Activation
energy of the reaction catalysed by bone alkaline phosphatase was
calculated according to the Arrhenius equation
In(k!/k2) = activation energy/R(l/Ti — 1/T2),
where k] and k2 fepresent catalytic activities at absolute temper-
atures, TI and T2, and R is the universal gas constant (8.314 J/mol
•K) (18). The Standard temperature interval for determination of
the apparent activation energy was 303.14-310.14 K (30.0-
37.0 °C). At both temperatures, bone alkaline phosphatase activity
was measured on a HITACHI 747 analyser (Boehringer, Mann-
heim, Germany) using the IFCC method.
Neuraminidase treatment of bone alkaline phosphatase
Wheat germ agglutinin precipitates from blood donors were resus-
pended s mentioned above in N-acetylglucosamine solution and
used s a bone alkaline phosphatase fraction. Samples were incu-
bated with neuraminidase (20 U/1; EC 3.2.1.18, from Clostridium
perfi-ingens\ purchased from Sigma Chemicals Co. (St Louis, MO,
USA) (15). Ten μΐ of neurarninidase were added to a 100 μΐ sam-
ple. After incubation for l h, 2 h, and 3 h at 37 °C, activation en-
ergy of bone alkaline phosphatase was evaluated and compared
with the blank.
Analytical performance of
bone alkaline phosphatase kits
Coefficients of Variation were calculated by analysing serum pools
(total alkaline phosphatase activity: 75.7 ± 22.2 U/l, mean bone
alkaline phosphatase activity: 36.8 ± 16.9 U/l, mean bone alkaline
phosphatase mass concentration: 17.5 ± 7.2 μέ/l). Between-run
CVs were obtained using data on 10 consecutive days.
Measurement of bone alkaline phosphatase activity by
lectin precipitation
The precipitation procedure was performed with the Iso-ALP test
kit (Boehringer, Mannheim, Germany). The assay utilizes wheat
germ agglutinin s precipitating agent based on the principle de-
scribed by Rosalki & Ying Foo (12) and simplified by Behr &
Barnert (15). The kit contains a solution of wheat germ agglutinin
in acetate buffer, pH 4.5, containing 20 ml/l Triton X-100 to pre-
vent co-precipitation of biliary alkaline phosphatase. We mixed
equal amounts (100 μΐ) of lectin solution and serum. After incuba-
tion for 30 minutes at room temperature,· the mixture was centri-
fiiged at 10 000 g for 2.5 min. Total alkaline phosphatase and resid-
ual alkaline phosphatase activity in the. supernatant were deter-
mined. Bone alkaline phosphatase activity was calculated using
the equation
bone alkaline phosphatase (U/l) = 1.118 X total activity (U/l)
- 2.35 X supernate activity (U/l) (16).
Measurement of bone alkaline phosphatase mass
concentration by immunoradiometric assay
Mass concentration of bone alkaline phosphatase was determined
making use of a solid phase, two site immunoradiometric assay
Thyroid quantitative analysis
In healthy blood donors and in hyperthyroidism patients, thyrotro^
pin (TSH, RIA-gnost, hTSH, Behringwerke AG, Marburg, Ger-
many) and free T4 (Amerlex-MAB* FT4, Kodak Clinical Diagnos-
tics Ltd, Amersham, UK) were assayed using commercial immuno-
assays.
Statistics
Data are given s mean ± S. D. Differences between groups were
compared using a two^tailed Mann-Whitney U-test. Correlation
analysis was performed with the Pearson correlation test.
Results
Mass and activity concentration of
bone alkaline phosphatase
Within- and between-run coQfficients of Variation (CV)
for the Iso-ALP kit were 3.5fend 5.9% respectively. The
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Tab. l Total alkaline phosphatase activity, bone alkaline phos-
phatase activity, bone alkaline phosphatase mass concentration,
bone alkaline phosphatase specific activity, and activation energy
in the study groups
Total alkaline phosphatase activity1)
Bone alkaline phosphatase activity1)
Bone alkaline phosphatase mass concentration1)
Bone alkaline phosphatase specific activity1)



























1) mean ± SD
2) p < 0.05 compared with blood donors; p < 0.001 compared
with osteoporosis
3) p < 0.001 compared with blood donors
4) p < 0.05 compared with blood donors
Tandem-R Ostase assay had a within-run CV of 4.1%
and a between-run CV of 7.2%. The bone alkaline phos-
phatase catalytic activity and mass concentration values
obtained in the different groups are shown in table 1.
Compared with the healthy blood donors, serum bone
alkaline phosphatase concentrations in the osteoporosis
and hyperthyroidism groups show a broader r nge. In
general, bone alkaline phosphatase mass and activity
concentration correlate well. Figure l depicts the corre-
lation between mass and activity concentration of bone
alkaline phosphatase: log y (serum bone alkaline phos-
phatase activity; U/l) = 1.0 log χ (serum bone alkaline
phosphatase mass concentration; μg/l) + 0.180,
r = 0.800, S^ = 34.7.
Correlation between total alkaline
phosphatase activity and bone alkaline
phosphatase
The total serum alkaline phosphatase activities in the
study groups are listed in table 1. Serum activity of bone
alkaline phosphatase generally shows a good correlation





Bone alkaline phosphatase [//g/l]
103
Fig. l Correlation between bone alkaline phosphat se mass and
activity concentration in the overall pbpulation, depicted on a loga-
rithinic scale: log y (serum activity concentration; /l) =? 1.0 log χ
(serum bone alkaline phosphatase mass concentration; μg/l)
H- 0.1 8, r = 0;800, S'yx
rum bone alkaline phosphatase activity; U/l) = 0.4 χ
(serum total alkaline phosphatase activity; U/l) - 1.176,
r = 0.840, S^ = 30.8. Similarly, serum bone alkaline
phosphatase mass concentration is correlated with the
total alkaline phosphatase activity in serum: y (serum
bone alkaline phosphatase mass concentration; μ§/1)
= 0.19 χ (serum total alkaline phosphatase activity; U/l)
+ 3.261, r = 0.889, Syx = 11.5.
Activity versus mass concentration of bone
alkaline phosphatase
In the blood donors, the activity : mass ratio of serum
bone alkaline phosphatase at 37 °C is 2.23 ± 1.32 U^g
(tab. 1). Between the osteoporosis and hyperthyroidism
groups, the bone alkaline phosphatase activity : mass
ratio is significantly different: 2 .41 ±2.10 U^g vs. 1.59
± 0.77 U^g (p < 0.001). In hyperthyroidism, the bone
alkaline phosphatase activity : mass ratio also differs
from that of the controls (p < 0.05). For all groups, the
bone alkaline phosphatase activity : mass ratio was
correlated with its serum activity concentration at 37 °C:
y (bone alkaline phosphatase activity: mass ratio; U^g)
= 0.06 χ (serum bone alkaline phosphatase activity; U/l)
+ 0.214, r = 0.832, S^ = 0.76 (blood donors); y (bone
alkaline phosphatase activity : mass ratio; U^g)
= 0.03 χ (serum bone alkaline phosphatase activity; U/l)
-l· 1.387, r = 0.761, Syx = 1.47 (osteoporosis); and y
(bone alkaline phosphatase activity: mass ratio; U^g)
= 0.01 χ (serum bone alkaline phosphatase activity; U/l)
+ 1.05, r = 0.572, Syx = 0.71 (hyperthyroidism).
Activation energy of bone alkaline
phosphatase
The catalytic quality of bone alkaline phosphatase, s
evaluated by determination of its activation energy, was
different between the study groups. In the healthy blood
donors, activation energy of the reaction catalysed by
bone alkaline phosphatase was 37.7 ± 5.9 kJ/mol. As
shown in table l, activation energy of bone alkaline
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 32, 1994 / No. 9
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phosphatase was increased in osteoporosis (63.3 ±11.8
kJ/mol, p < 0.001) and in hyperthyroidism (58.5 ± 18.8
kJ/mol, p < 0.05).
Effects of neuraminidase treatment on
activation energy
Neuraminidase treatment of the bone alkaline phospha-
tase fractions obtained from 4 healthy blood donors re-
sulted in an increase in activation energy. Prior to treat-
ment, the activation energy of bone alkaline phosphatase
was 38.0 ± 5.1 kJ/mol. Blank values (untreated sam-
ples) remained stable during the experiment. After l h
incubation, the activation energy of bone alkaline phos-
phatase was 57.0 ± 1.2 kJ/mol (p < 0.01). After 2 h and
3 h, the activation energy rose to 66.1 ± 8.9 kJ/mol and
75.3 ±11.0 kJ/mol respectively.
Effects of age, sex, and disease
For all groups, we found no correlations between the
subjects' age and total alkaline phosphatase activity,
bone alkaline phosphatase activity, bone alkaline phos-
phatase mass concentration, bone alkaline phosphatase
activity: mass ratio, or activation energy. Similarly,
there were no sex differences for these quantities.
In the osteoporosis group, patients with postmenopausal
osteoporosis showed higher (p < 0.05) total alkaline
phosphatase activity and bone alkaline phosphatase
mass (tab. 2). A history of fractures was not significantly
correlated with a change in bone alkaline phosphatase
values: 26.6 ± 25.1 U/l and 9.3 ± 1.9 μg/l (subgroup
with bone fractures) vs. 25.5 ± 37.9 U/l and 9.2 ±3.7
μg/l for the subgroup without fractures. The axial bone
densitometry (expressed s age- and sex-matched z
scores) correlated well with the bone alkaline phospha-
tase values: y (bone alkaline phosphatase activity: U/l)
= 12.84 χ (z-score) + 42.0; r = 0.634, Syx = 14.33 and
y (bone alkaline phosphatase mass; μg/l) = 1.66 χ (ζ-
score) + 11.9; r = 0.450, Syx = 3.02.
In the reference population, thyrotropin and FT4 values
were respectively 1.68 ± 1.22 mU/1 and 14 ± 2 ng/1. In
the hyperthyroidism group, thyrotropin and FT4 values
were 0.02 ± 0.02 mU/1 (p < 0.001) and 29 ± 12 ng/1
(p < 0.05). According to the FT4 values, the hyperthy-
roidism group could be subdivided into patients with
FT4 less than 18 ng/1 (n = 38), FT4 values between 18
and 30 ng/1 (n = 33), and FT4 values > 30 ng/1 (n = 7).
No differences in bone alkaline phosphatase mass or ac-
tivity were found between these s bgroups. No signifi-
cant correlations could be calculated between FT4 vaU
ues and total alkaline phosphatase activity, bone alkaline
phosphatase activity, bone alkaline phosphatase mass
concentration, bone alkaline phosphatase activity : mass
ratio, or activation energy.
Discussion
In this study, we used two new c mmercially available
methods for measuring the mass and activity concentra-
tion of bone alkaline phosphatase. Analyses were per-
formed on a st dy group of healthy blood donors and
patients with osteoporosis and hyperthyroidism, a dis-
ease associated with inetabolic bone disease (19). In a
recent multUcentre evaluation, the Iso-ALP lectin pre-
cipitation kit was found to be suitable for quantitation
of serum bone alkaline phosphatase in routine analysis
(16). We comp red this method with a recently devel-
oped solid phase immunoassay (Tandem-R Ostase). In (l
general, we noted that serum bone alkaline phosphatase
mass and activity concentration correlate well. In our
opinion, both IRMA and lectin precipitation methods of-
fer a resolution that is equivalent, if not superior, to any
other technique for separating bone alkaline phosphatase
from liver alkaline phosphatase. The quality of the Sepa-
ration and technical simplicity mean that both assays
provide a useftil alternative for measuring bone alkaline
phosphatase. However, in each of the used methods, the
binding is incomplete and not completely specific.
A broad Variation from normal to very high serum bone
alkaline phosphatase activities is found in the osteoporo-
sis and hyperthyroidism groups, dependent on the clin-
ical picture and the level of bone turnover. In patients
with less drainatic skeletal involvement, any changes in
Tab. 2 Osteoporosis classification and bone alkaline phosphatase
Total alkaline phosphatase activity1)
Bone alkaline phosphatase activity1)
Bone alkaline phosphatase mass concentration1)
























mean ± SD 2) p < 0.05 compared with others
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bone alkaline phosphatase only make a small contribu-
tion to the circulating pool of the enzyme (1). The eleva-
tion of bone alkaline phosphatase in serum is related to
bone rebuilding and not to bone resorption, and thus the
levels may be normal in the early stages of osteoporosis
(20). Serum bone alkaline phosphatase increases äs the
condition deteriorates and resorption and remodelling
co-exist. An increase of bone alkaline phosphatase in
hyperthyroidism can be explained by a direct action of
thyroid hormones on osteoblasts (19).
Using both bone alkaline phosphatase mass and activity
concentration, we calculated the activity : mass ratio of
the enzyme in the study groups. The activity : mass ratio
of serum bone alkaline phosphatase at 37 °C is de-
creased in hyperthyroidism. For all study groups, the ac-
tivity : mass ratio of bone alkaline phosphatase is corre-
lated with its serum activity at 37 °C and is thus depen-
; dent on the degree of bone turnover.
j In the temperature interval 30 °C-37 °C, the activation
energy of the reaction catalysed by bone alkaline phos-
phatase also differed. In both osteoporosis and hyperthy-
! roidism, the activation energy of bone alkaline phospha-
! tase is increased, indicating a loss of catalytic quality
of the enzyme. These results suggest the existence of a
thermodynanüc heterogeneity of bone alkaline phospha-
tase in metabolic bone disease.
Our findings are in agreement with those of several au-
thors, who suggested the existence of a posttranslational
microheterogeneity of bone alkaline phosphatase (20).
Multiple bands of bone alkaline phosphatase have been
identified by isoelectric focusing of sera from heälthy
adults (21, 22). After Separation of alkaline phosphatase
isoforms, using high performance liquid chromatogra-
phy (HPLC) on anion exchange columns, two bone frac-
tiohs were found in bone tissue extracts and in serum
from a growing child (23). Furthermore, one of the bone
fractions was preferentially elevated in osteoporosis, os-
teomalacia, bone metastases and Pagei's disease (24).
Similarly, two bands of bone alkaline phosphatase were
separated using affinity electrophoresis of human serum
in agarose gel containing wheat germ lectin, suggesting
differences in the affinity for lectin and/or the number
of N-acetylglucosamine and sialic acid residues (25).
Differences in glycosylation and molecular mass have
been shown between neonatal and adult forms of bone
alkaline phosphatase (26). Carbohydrate side chain
heterogeneity of bone alkaline phosphatase has also
been suggested in patients with Pagefs disease and
hyperparathyroidism (26). Furthermore, high perfor-
mance affinity chromatography (HPAC) against wheat-
germ lectin demonstrated a change in the glycosylation
pattern of bone alkaline phosphatase in bone disease
(27).
In conclusion, using two alternative methods for meas-
uring serum bone alkaline phosphatase mass and activity
concentration, we were able to demonstrate a hetero-
geneity of bone alkaline phosphatase in metabolic bone
disease.
Our findings suggest that a different posttranslational
modification of bone alkaline phosphatase occurs in
pathological conditions.
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